Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Stock Up 1.3 %

Shares of Check-Cap stock opened at $2.29 on Tuesday. The stock has a market capitalization of $13.40 million, a price-to-earnings ratio of -0.76 and a beta of 0.27. Check-Cap has a twelve month low of $1.27 and a twelve month high of $4.63. The company has a 50-day simple moving average of $2.25 and a two-hundred day simple moving average of $2.57.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.